On 30 October 2025, PuraPharm Corporation Limited (1498) completed its Patent Licence Agreement and a separate Subscription Agreement. Under the Patent Licence Agreement, 93,488,372 new shares were issued at HK$0.43 per share, representing approximately 17.45% of the company’s enlarged share capital. Concurrently, the company also issued 46,512,000 new shares at HK$0.43 per share through a subscription, totaling around 8.68% of the enlarged capital.

Following these transactions, the total number of issued shares rose from 395,897,275 to 535,897,647. Before completion, Mr. Chan and his associates collectively held around 57.13% of the company. After the issuance of both consideration and subscription shares, their holding stands at approximately 42.21%, while the new shareholder under the Patent Licence Agreement holds 17.45%, and the subscriber holds 8.68%.